NASDAQ: EMBCEmbecta Corp Stock
$10.89+0.01 (+0.09%)
Updated Apr 24, 2024
EMBC Price
$10.89
Fair Value Price
N/A
Market Cap
$627.03M
52 Week Low
$9.93
52 Week High
$32.00
P/E
11.34x
P/B
-0.79x
P/S
0.97x
PEG
0.11x
Dividend Yield
1.38%
Revenue
$1.12B
Earnings
$55.30M
Gross Margin
66.6%
Operating Margin
15.41%
Profit Margin
4.9%
Debt to Equity
-2.54
Operating Cash Flow
-$6M
Beta
0.88
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
EMBC Overview
Embecta Corp. is a medical device company offering various solutions to people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist with the management of diabetes. The company sells its products to wholesalers and distributors in the U.S and internationally. Embecta was founded in 1924 and is based in Parsippany, NJ.
Zen Score
–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EMBC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EMBC ($10.89) is trading below its intrinsic value of $39.03, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EMBC is good value based on its earnings relative to its share price (11.34x), compared to the US market average (41.27x)
P/E vs Market Valuation
EMBC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more EMBC due diligence checks available for Premium users.
Be the first to know about important EMBC news, forecast changes, insider trades & much more!
EMBC News
Valuation
EMBC fair value
Fair Value of EMBC stock based on Discounted Cash Flow (DCF)
Price
$10.89
Fair Value
$22.86
Undervalued by
52.37%
EMBC ($10.89) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EMBC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
11.34x
Industry
48.25x
Market
41.27x
EMBC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EMBC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
EMBC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.79x
Industry
3.52x
EMBC price to earnings growth (PEG)
For valuing profitable companies with growth potential
EMBC is good value based... subscribe to Premium to read more.
PEG Value Valuation
EMBC's financial health
Profit margin
Revenue
$277.3M
Net Income
$20.1M
Profit Margin
7.2%
EMBC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EMBC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$2.0B
Debt to equity
-2.54
EMBC's short-term assets ($719.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EMBC's long-term liabilities ($1.68B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EMBC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EMBC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.1M
Investing
-$2.7M
Financing
-$13.5M
EMBC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EMBC vs Medical Stocks
Embecta Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.